Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective (Q38115487)

29 August 2017

title

Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective (English)

1 reference

29 August 2017

Anna-Sophia Rauch

1

1 reference

29 August 2017

W Wolfgang Fleischhacker

series ordinal

2

1 reference

29 August 2017

publication date

1 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

27

1 reference

29 August 2017

issue

8

1 reference

29 August 2017

page(s)

637-652

1 reference

https://scigraph.springernature.com/pub.10.1007/s40263-013-0083-9

29 August 2017

exact match

0 references

cites work

Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Long-acting risperidone: a review of its use in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Second-generation antipsychotic long-acting injections: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Remission in schizophrenia: proposed criteria and rationale for consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Prediction of outcome in schizophrenia. III. Five-year outcome and its predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Rating of medication influences (ROMI) scale in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Insight: demographic differences and associations with one-year outcome in schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Insight in early psychosis: a 1-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Emotion processing in schizophrenia: fMRI study of patients treated with risperidone long-acting injections or conventional depot medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

A differential neural response in the human amygdala to fearful and happy facial expressions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

A specific neural substrate for perceiving facial expressions of disgust

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectable

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Measurement of premorbid adjustment in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

A meta-analysis of the efficacy of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Long-acting risperidone and oral antipsychotics in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

Psychiatrists' attitudes to maintenance medication for patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0083-9

A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with Schizophrenia

21 January 2018

1 reference

12 December 2020

Deltoid injections of risperidone long-acting injectable in patients with schizophrenia

1 reference

12 December 2020

Attitudes of psychiatrists toward antipsychotic depot medication

1 reference

12 December 2020

A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia

1 reference

12 December 2020

The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10

1 reference

12 December 2020

Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study

1 reference

12 December 2020

Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.

1 reference

12 December 2020

An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.

1 reference

12 December 2020

A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.

1 reference

12 December 2020

Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching

1 reference

12 December 2020

A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity

1 reference

12 December 2020

A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia

1 reference

12 December 2020

Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning

1 reference

12 December 2020

Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic

1 reference

12 December 2020

The attitude of patients towards antipsychotic depot treatment

1 reference

12 December 2020

1 reference

12 December 2020

Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months.

1 reference

12 December 2020

Personality as a Predictor of the Variability of Insight in Schizophrenia

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.

1 reference

12 December 2020

10.1007/S40263-013-0083-9

Identifiers

DOI

1 reference

29 August 2017

1 reference